Life Sciences

  • August 05, 2026

    These Firms Are Picking Up The Most PTAB Work

    Intellectual property heavyweight Fish & Richardson PC remains the busiest firm in front of the Patent Trial and Appeal Board, as it again secured the top spot on a list of firms with the most PTAB trials over the past three years.

  • August 05, 2026

    Fenwick-Led Attovia Therapeutics Prices Upsized $289M IPO

    Early-stage biotechnology company Attovia Therapeutics hit the public markets on Wednesday after it raised $289 million in its upsized initial public offering.

  • August 05, 2026

    Glenmark Pharma Hit With Safety Suit After Carvedilol Recalls

    Glenmark Pharmaceuticals' generic drug carvedilol, used to treat high blood pressure and congestive heart failure, was misrepresented as therapeutically equivalent to the brand-name drug Coreg but contained undisclosed nitrosamine impurities that changed its strength, quality and safety profile, according to a proposed class action filed Tuesday in Washington federal court.

  • August 05, 2026

    Revive Rx Can't End Eli Lilly's Suit Over Tirzepatide Drugs

    A Texas federal judge has denied Revive Rx's bid to end Eli Lilly and Co.'s remaining unfair competition claims over the compounding pharmacy's sales of allegedly unapproved tirzepatide weight loss drugs that Eli Lilly says compete with Mounjaro and Zepbound, rejecting Revive's argument that compounded drugs fall outside state "new drug" laws.

  • August 05, 2026

    PTAB Filings Crashed After Squires And Stewart's Shake-Ups

    The number of America Invents Act filings with the Patent Trial and Appeal Board cratered at the end of 2025 after the U.S. Patent and Trademark Office enacted policies that made the petitions a disfavored route for challenging patents, according to a new report.

  • August 04, 2026

    New Patent Suits Surge As PTAB Challenges Get Tougher

    More patent suits were filed in 2025 than in any year in the past decade, according to a new report, an increase attorneys said is likely tied to new U.S. Patent and Trademark Office policies that have made it harder to challenge patents.

  • August 04, 2026

    These Firms Are Landing The Most Patent Litigation Work

    Rabicoff Law and Ramey LLP have maintained their roles as top patent suit filers, while Fish & Richardson PC and Gillam & Smith LP have remained leaders on defense teams, according to Lex Machina's annual patent litigation report.

  • August 04, 2026

    3rd Circ. Won't Give Ex-Olympus Exec Another Go At FCA Suit

    The Third Circuit has declined to revive a whistleblower suit by Olympus Corp.'s former employee who claimed he was fired after reporting FDA regulatory violations, ruling Tuesday that he failed to state a retaliation claim under the False Claims Act since he didn't link his concerns to a reasonable belief that Olympus defrauded the government.

  • August 04, 2026

    Kirkland, Jones Day Guide P&G's $3.8B Buy Of Thorne

    Procter & Gamble is acquiring supplements company Thorne from L Catterton for $3.8 billion in cash, with Kirkland & Ellis LLP and Jones Day serving as legal advisers in the transaction, the companies announced Tuesday.

  • August 04, 2026

    Biotech Founder Claims He Was Excluded From GSK Deal

    The co-founder of a defunct biotech company said his business partners froze him out of an asthma drug venture that was eventually snapped up by GlaxoSmithKline for $1.4 billion, in a complaint filed in Massachusetts state court.

  • August 04, 2026

    Saxena White Seeks To Lead GeneDX AI Acquisition Row

    Saxena White PA has asked a Connecticut federal court to appoint it as lead counsel in a securities class action accusing the biopharma company GeneDX Holdings Corp. of misrepresenting the benefits of a $51 million acquisition, and to name two public retirement systems as lead plaintiffs.

  • August 04, 2026

    Fed. Circ. Won't Reopen Lidocaine Patch Patent Suit

    The Federal Circuit on Tuesday declined to reinstate a suit accusing Florida pharmaceutical manufacturer Aveva Drug Delivery Systems of infringing a trio of lidocaine patch patents, shooting down arguments that a lower court misinterpreted key patent language.

  • August 04, 2026

    Workers Say Trump's Gold Card Lets Rich Jump Visa Line

    Professional, skilled workers seeking employment-based visas urged a D.C. federal judge not to toss their lawsuit challenging the gold card visa program, arguing they will suffer injury because the expedited application allows wealthy individuals to skip ahead in line.

  • August 04, 2026

    Bellwether Jury Awards $88M In Covidien Hernia Mesh Trial

    A Massachusetts federal jury awarded $88 million Tuesday to a man who claimed he was injured by a Covidien LP-made hernia mesh, in the first case to reach a verdict of thousands pending against the Medtronic unit.

  • August 03, 2026

    Albertsons Says Wash. Slow To Warn Of Bad Drug Prescribers

    Washington regulators didn't notify pharmacies or patients about doctors' potentially improper opioid prescribing until months after receiving complaints, Albertsons' counsel told a Seattle judge Monday, as the bench trial over Washington's claims the pharmacy chain helped fuel the state's overdose crisis entered its fourth week.

  • August 03, 2026

    Calif. Justices Back Gilead Over Nondefective Drug Liability

    The California Supreme Court on Monday held that Gilead Sciences Inc. shouldn't face a negligence claim alleging it declined to market a safer HIV drug in order to maximize profits from an older drug with more harmful side effects, rejecting a novel theory that would expose drugmakers to broader liability.

  • August 03, 2026

    7th Circ. Backs OB-GYN's 10-Year Healthcare Fraud Sentence

    The Seventh Circuit has upheld a 10-year prison sentence for a former obstetrician-gynecologist over a multimillion-dollar healthcare fraud scheme, saying the district judge made no clear error in applying an enhancement to her sentence for performing invasive and medically unnecessary procedures on patients without their informed consent.

  • August 03, 2026

    Novo False-Ad Claims Against Telehealth Co. Fail, For Now

    A New York federal court tossed a false advertising suit by Novo Nordisk against a telehealth company that markets compounded weight loss medications, finding the pharmaceutical giant failed to point to literal or implied false statements made by the company.

  • August 03, 2026

    4 Firms Steer Curium's $8B Lantheus Take-Private Deal

    Private equity-backed radiopharmaceutical company Curium on Monday announced plans to acquire fellow radiopharmaceutical company Lantheus Holdings Inc. in an $8 billion take-private deal built by four law firms.

  • August 03, 2026

    Sandoz Settles States' Generics Price-Fixing Cases For $450M

    Sandoz reached a settlement with a coalition of state enforcers on Monday, agreeing to pay $450 million to end claims against it in several cases targeting alleged price-fixing in the generic-drug industry.

  • August 03, 2026

    Baker Botts Hires Litigators In DC And London

    Baker Botts LLP has hired two litigators who focus on representing companies in highly regulated and technically sophisticated industries as partners in its offices in Washington, D.C., and London, the firm announced Monday.

  • August 03, 2026

    Pfizer COVID Vaccine Suit Needs 3-Judge Court, Panel Finds

    The D.C. Circuit has revived a couple's suit against Pfizer Inc., federal officials and a pediatrician's office alleging their child died after receiving the COVID-19 vaccine, saying federal law required a three-judge court to decide motions to dismiss, not the single judge who tossed the case.

  • August 03, 2026

    KKR Buying Integer For $5.7B In Kirkland, Davis Polk-Led Deal

    KKR said Monday that it will acquire medical device company Integer Holdings Corp. in an all-cash transaction with a roughly $5.7 billion enterprise value, with Kirkland & Ellis LLP and Davis Polk & Wardwell LLP advising on the transaction. 

  • August 03, 2026

    Bath Product Maker Vi-Jon Hits Ch. 11 With $25M Talc Deal

    Private-label dry bath product maker Vi-Jon LLC filed for Chapter 11 protection in Delaware with a proposed plan to channel talc injury claims into a trust to be funded by $25 million of cash and the contribution of certain insurance rights.

  • August 03, 2026

    Former Gates Foundation Deputy GC Joins Arnold & Porter

    The former deputy counsel of the Gates Foundation has joined Arnold & Porter Kaye Scholer LLP's life sciences and technology transactions teams in the corporate and finance practice, the firm announced Monday.

Expert Analysis

  • After Durnell, Connecting Science And Causation Will Be Key

    Author Photo

    The U.S. Supreme Court's June 25 decision in Monsanto v. Durnell narrowed label-based failure-to-warn claims — meaning that going forward, viable theories will depend even more on whether experts can reliably connect scientific evidence to the causal proposition the law requires, says Alex Smolak at Weill Cornell Medicine-Qatar.

  • Series

    Choral Singing Makes Me A Better Lawyer

    Author Photo

    Singing in the New York City Bar Chorus — a hobby partly inspired by the late U.S. District Judge Richard Owen, who infused my clerkship year with opera music — has improved my legal career by refining my abilities to listen, exude confidence and develop emotional intelligence, says Bonnie Baker at Friedman Kaplan.

  • Attorney Mental Health Is An Ethical Obligation In The AI Era

    Author Photo

    As attorneys cope with the increasing unpredictability that artificial intelligence and constant policy changes have created, particularly in practice areas where they carry the emotional weight of clients’ most consequential life events, otherwise soft discussions about self-care are a matter of professional competence, says attorney Jack Jrada.

  • The Case For Using Final-Offer Damages Forms In IP Suits

    Author Photo

    Recent Federal Circuit decisions, such as Ollnova v. Ecobee, that scrutinize verdict forms in patent infringement disputes potentially render the final-offer damages selection procedure more attractive, though it should not be seen as a replacement for patent damages doctrine, says Brandon Theiss at Addy Hart.

  • Key Tips For Patenting Antibody-Drug Conjugate Inventions

    Author Photo

    Recent decisions highlight the significant challenges that can arise when patenting antibody-drug conjugates, which require strategic considerations for satisfying heightened written description and enablement requirements, says Xiaoban Xin at FisherBroyles.

  • $885M IBS Drug Verdict Tests Pay-For-Delay Limits

    Author Photo

    The outcome in the Amitiza Antitrust Litigation is significant because it is the first jury trial win for private antitrust plaintiffs in a suit challenging a patent settlement reverse payment since the U.S. Supreme Court adopted the rule-of-reason legal framework in 2013, offering a blueprint for pay-for-delay claims, say attorneys at Katten.

  • Series

    Power To The Paralegals: Burnout As A Structural Problem

    Author Photo

    Law firm leadership can best retain their paralegals not by encouraging self-care, but by seeking top-down structural solutions for the quiet proliferation of responsibilities and the vicarious exposure to client trauma that particularly drive burnout in this vital role, says Erika Sneeringer at Brockstedt Mandalas.

  • Class Actions At The Circuit Courts: June Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses five recent rulings from cases involving allegations of internet data misuse, consumer fraud claims, immigration, insurance and First Amendment violation claims.

  • Takeaways From 1st Del. Ruling Applying Moelis Amendments

    Author Photo

    Delaware corporations should carefully review contractual arrangements and governance documents following the Court of Chancery's recent enforcement of a non-Delaware forum selection clause in a CEO's employment agreement under 2024 amendments to the state's General Corporation Law, say attorneys at Morgan Lewis.

  • Ill. Law Firm MSO Bill Clashes With Court Power, Ethics Rules

    Author Photo

    An Illinois bill prohibiting law firms from certain business arrangements with management service organizations, sent to the governor for signature last week, encroaches upon the courts' constitutional powers and goes beyond the Illinois Rules of Professional Conduct in regulating investment in law-related services, says Matthew O’Hara at Smith Gambrell.

  • The Future Of WDTX Patent Litigation After Judge Albright

    Author Photo

    With U.S. District Judge Christopher Wolfe set to take over much of Judge Alan Albright's patent infringement docket in the Western District of Texas later this year, attorneys should prepare for potential differences in Judge Wolfe's approach to the court's high volume of patent litigation, say attorneys at Sidley Austin.

  • Opinion

    State Courts Must Be Gatekeepers Of Expert Testimony

    Author Photo

    Based on my experience in the state judiciary, emulating federal courts' role as gatekeepers of expert witness testimony would help state court judges maintain the appearance of impartiality and assist juries, thus enhancing the overall confidence people have in their justice system, says Lorie Gildea at Greenberg Traurig.

  • 5 Key Factors Behind USPTO's Inter Partes Review Decisions

    Author Photo

    Though U.S. Patent and Trademark Office Director John Squires has drawn criticism for failing to explain his reasoning in inter partes review decisions, his recent precedential order in Magnolia v. Kurin provides five important insights into his decision-making process, says Christopher Loh at Venable.

  • Series

    Moshing Makes Me A Better Lawyer

    Author Photo

    Entering a mosh pit is much like entering the practice of law — it is difficult, you have to know both the written and unwritten rules, and conduct yourself according to the expectations of each community, says Christopher Deubert at Constangy Brooks.

  • High Court Ruling Casts Doubt On Status-Based Gun Bans

    Author Photo

    The U.S. Supreme Court’s recent ruling in U.S. v. Hemani demonstrates that the justices are increasingly skeptical of broad theories of categorical disarmament and clarifies that dangerousness cannot simply be presumed from one's status or membership in a statutory category, such as illegal drug use, says Lee Francis at Widener Law.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.